Raymond James Financial Services Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,900	Closed	-$4.53K	–	3374
2023 Q2	$4.53K	Sell	13,900 -300	-2%	-$108	﹤0.01%	3226
2023 Q1	$6.11K	Buy	+14,200	New	+$7.49K	﹤0.01%	3238
2019 Q4	–	Sell	-15,486	Closed	-$117K	–	2964
2019 Q3	$117K	Buy	15,486 +2,164	+16%	+$24.4K	﹤0.01%	2612
2019 Q2	$181K	Buy	+13,322	New	+$154K	﹤0.01%	2563

Other funds holding ZYNE

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Raymond James Financial Services Advisors's ZYNE Position: Q3 2023 in Review

Raymond James Financial Services Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2023, closing a stake of 13,900 shares — an estimated $4.53K sold.

Raymond James Financial Services Advisors first reported a position in ZYNE in Q2 2019 and held it in 4 quarters. The position peaked at $181K in Q2 2019. 43 funds tracked by Wall St. Rank hold ZYNE as of Q3 2023.

Raymond James Financial Services Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
Raymond James Financial Services Advisors sold 13,900 Zynerba Pharmaceuticals, Inc shares in Q3 2023, an estimated $4.53K.
Raymond James Financial Services Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2019 and held it in 4 quarters.
Raymond James Financial Services Advisors's Zynerba Pharmaceuticals, Inc position peaked at $181K in Q2 2019.
43 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2023, filed 24 Oct 2023.